Healthcare -
Biotechnology - NASDAQ - US
$ 4.91
-0.607 %
$ 222 M
Market Cap
-7.33
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Y-mAbs Therapeutics, Inc.
| Revenue | 87.7 M |
| Cost Of Revenue | 15.3 M |
| Gross Profit | 72.4 M |
| Operating Expenses | 104 M |
| Operating Income | -31.2 M |
| Other Expenses | -1.54 M |
| Net Income | -29.7 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 87.7 | 84.8 | 65.3 | 34.9 | 20.8 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 15.3 | 11.4 | 7.6 | 2.5 | 2.2 | 0.2 | 29 K | 0 | 0 |
| Gross Profit | 72.4 | 73.4 | 57.7 | 32.4 | 18.5 | (0.2) | 29 K | 0 | 0 |
| OPERATING INCOME | |||||||||
| Operating Expenses | 103.6 | 99.1 | 152.5 | 147.8 | 138.5 | 83.0 | 43.2 | 19.2 | 17.0 |
| Selling, General and Administrative Expenses | 54.6 | 44.9 | 60.9 | 54.6 | 44.8 | 19.5 | 9.0 | 4.9 | 3.2 |
| Research and Development Expenses | 49.0 | 54.2 | 91.6 | 93.2 | 93.7 | 63.5 | 34.3 | 14.3 | 13.9 |
| Operating Income | (31.2) | (25.7) | (94.8) | (115.4) | (119.9) | (83.0) | (43.2) | (19.2) | (17.0) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 0 | 0 | 0.8 | 1.9 | 0.6 | 2.0 | -- | 0 | 0 |
| Total Other Income | 1.4 | 4.8 | (0.8) | 60.2 | 0.6 | 2.0 | 44 K | 83 K | 18 K |
| Pre-Tax Income | (29.8) | (20.9) | (95.6) | (55.3) | (119.3) | (81.0) | (43.3) | (19.2) | (17.1) |
| NET INCOME | |||||||||
| Tax Provision | (0.1) | 0.6 | 0.8 | 1.1 | (1.0) | (2.1) | 44 K | (19.2) | (17.0) |
| Net Income | (29.7) | (21.4) | (96.3) | (56.3) | (118.3) | (78.9) | (43.3) | (19.2) | (17.1) |
| EPS | 0.67 | 0.49 | 2.2 | 1.3 | 2.95 | 2.24 | 1.5 | 0.58 | 0.51 |